. Author manuscript; available in PMC: 2019 Jul 10.

Published in final edited form as: J Craniomaxillofac Surg. 2017 Jan 31;45(4):595–600. doi: 10.1016/j.jcms.2017.01.020

Table 2.

The number (%) of patients with and without xerostomia fulfilling / violating the two criteria provided by the QUANTEC guidelines, and the related mean dose to the contralateral and the ipsilateral parotid glands (Dmean_contra, Dmean_ispi), as well as the relative risks (RRs), 95% confidence intervals (95%CIs), and p-values for the two guidelines.

		*Dmean*_contra≤20 Gy		*Dmean*_contra>20 Gy
Follow-up		*N (%) Fulfilled*	*Dmean_contra [Gy]*	*N (%) Not fulfilled*	*Dmean_contra [Gy]*	RR	*95% CI*	p
<6m	Xerostomia	3 (10)	11.2±6.7	12 (46)	28.3±10.7	2.3	1.4–3.7	0.001*
	No Xerostomia	26 (90)	10.6±6.0	14 (54)	24.2±2.5
6–24m	Xerostomia	1 (4)	12.7±0.0	9 (32)	25.9±2.5	2.0	1.4–3.0	0.0004*
	No Xerostomia	24 (96)	10.5±6.0	19 (68)	26.1±8.9
		*Dmean*_contra≤25Gy, Dmean_ipsi≤25 Gy		*Dmean*_contra>25Gy, Dmean_ipsi>25 Gy
Follow-up		*N (%) Fulfilled*	*Dmean_ipsi [Gy]*	*N (%) Not fulfilled*	*Dmean_ipsi [Gy]*	RR	*95% CI*	p
<6m	Xerostomia	1 (7)	23.2±0.0	14 (34)	45.3±20.2	1.4	1.1–1.8	0.01*
	No Xerostomia	13 (93)	13.5±8.9	27 (66)	31.2±9.6
6–24m	Xerostomia	1 (8)	24.5±0.0	9 (22)	41.5±13.5	1.2	0.9–1.6	0.13
	No Xerostomia	12 (92)	13.8±8.1	32 (78)	35.3±16.2